Evidence map›Paper›PMID 40462809›Full record

ArticleCureus2025

A Rare Presentation of a Neuroendocrine Tumor: A Case Report.

Elisheva Knopf, Camryn R Marshall, Leah Leidy, Parvathi Perumareddi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elisheva KnopfDepartment of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA.
Camryn R MarshallDepartment of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA.
Leah LeidyDepartment of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA.
Parvathi PerumareddiDepartment of Family Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine tumors (NETs) are slow-growing, rare malignancies that originate from neuroendocrine cells and may be classified as functional, secreting hormones that produce clinical symptoms, or non-functional, often remaining asymptomatic until advanced stages. Primary gastrointestinal NETs in the esophagus (E-NETs) are rare, accounting for only 0.4%-2% of esophageal malignancies. Due to their rarity, often subtle early symptoms, and being mostly non-functional tumors, they are frequently diagnosed at an advanced stage with metastasis. This case report describes a patient who presented to the emergency department (ED) with a three-week history of weakness, hypophonia, and dysphonia, two months after carpal tunnel surgery. The patient had a past medical history (PMH) significant for hypertension and hypothyroidism and had no recent symptoms or medical concerns upon presenting for her preoperative examination for carpal tunnel surgery a few months prior. Before this preoperative appointment, she had an established primary care physician (PCP); however, she never had regular follow-ups or consistent monitoring. The patient's initial workup in the ED revealed hypercalcemia and elevated liver enzyme levels. In addition to these abnormal lab results, a subsequent right upper quadrant ultrasound showed multiple lesions in the liver, indicative of metastasis. The next day, the patient had an abdominal CT scan performed, which revealed wall thickening in the distal esophagus, suggestive of neoplasm or malignancy. The tumor was thought to have originated at the gastroesophageal junction and metastasized to the liver. The patient had a poor prognosis and passed away from the metastatic tumor within two weeks of diagnosis. This case underscores the aggressive nature and atypical presentations of E-NETs, including rare paraneoplastic syndromes, such as hypercalcemia. It also underscores that serious malignancies can develop in patients without traditional risk factors. While standardized guidelines for E-NET follow-up and management remain limited, this case reinforces the importance of maintaining a high index of suspicion for atypical symptoms and ensuring adherence to routine preventive care, which may facilitate earlier detection of rare but aggressive tumors.

Indexed as

disease preventionhepatic metastasishypercalcemia of malignancyneuroendocrine tumorprimary care

Identifiers

PMID40462809
PMCPMC12129828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.